Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Ph 2b Trial of IGV-001 in Newly Diagnosed GBM February 5, 2025
Patient Enrollment milestone reached for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM January 28, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors January 15, 2025
Novel CPT1 pathway inhibitor received Orphan Drug Designation from the FDA for treating malignant gliomas January 15, 2025
NDA submitted to US FDA for Accelerated Approval for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma January 7, 2025
NDA for Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma to be submitted Before Year-End December 18, 2024
Patient Enrollment Expanded for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM as UVA Cancer Center Doses First Patient December 4, 2024
SRN-101 announced as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA November 26, 2024
Eflornithine and Lomustine Combination Shows Clinically Meaningful Improvements in OS and PFS in Patients with Recurrent Astrocytoma IDH Mutant Grade 3 November 26, 2024
Type C Meeting granted with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed GBM November 13, 2024
Positive TNG462 Clinical Data reported and Update provided on PRMT5 Development Program November 12, 2024
Orphan Drug Designation by US FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma November 12, 2024
Autologous Dendritic Cell Vaccine DOC1021 Yields 93% 12-Month Survival for GBM Patients October 8, 2024
Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance DOC1021 into a Ph 2 Clinical Trial October 8, 2024
Ph 1 Data of Concurrent Paxalisib + RT in Patients with Solid Tumor Brain Mets or Leptomeningeal Mets Harboring PI3K Pathway Mutations announced October 8, 2024
